Apr 25, 2023 / 07:00PM GMT
John Valliant - Fusion Pharmaceuticals, Inc. - CEO
Thank you, and thank you, everyone, for attending. So I'm very excited to talk to you about the radiopharmaceutical field, which is undergoing a tremendous resurgence. It's a field that I've been in for 30 years. And one of the exciting parts about this idea of targeting radiation to specific cancer cells builds on the success of external beam radiation therapy. And so the idea of being able to use radiation to treat metastatic cancers is an idea that's been around for a number of years. There's some early promising clinical data, but we're seeing a tremendous resurgence in the field.
And so the idea is leverage the very simple mechanism of action associated with how radiation kills cells, but then use targeting molecules to bring radiation inside the tumor cells to cause largely double-strand DNA break and [leafill] kills to the tumor cell. It is a true type of precision medicine because one of the powers of the radiopharmaceutical field is you can see where your drug is going, the ability to image a patient, identify target mediated uptake in
Fusion Pharmaceuticals Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers